Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study - C3G_ECUL

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030164

Enrollment

Registered

2022-09-16

Start date

2022-09-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N03.5

Interventions

Group 1: Course of glomerular filtration rate, proteinuria, hematuria in subjects with histopathologically-proven C3 Glomerulopathy

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age>= 18 years, histopathological diagnosis of C3G.

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

Measure	Time frame
Positive outcome: > 30% decrease of eGFR at the end of Eculizumab treatment. Stable outcome: as eGFR± 30% at the end of Eculizumab treatment. Negative outcome: > 30% increase of eGFR at the end of Eculizumab treatment.	—

Secondary

Measure	Time frame
Positive outcome: > 30% decrease of Proteinuria/Hematuria at the end of Eculizumab treatment. Stable outcome: as Proteinuria/Hematuria ± 30% at the end of Eculizumab treatment. Negative outcome: > 30% increase of Proteinuria/Hematuria at the end of Eculizumab treatment.	—

Countries

Germany

Contacts

Public ContactThomas Welte

Universitätsklinikum Freiburg, Medizinische Klinik IV

thomas.welte@uniklinik-freiburg.de0049-761-270-33470

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026